共 169 条
[1]
Feigin VL(2020)Burden of neurological disorders across the US from 1990–2017: a global burden of disease study JAMA Neurol 78 165-176
[2]
Vos T(2020)Burden of illness among people with migraine and ≥ 4 monthly headache days while using acute and/or preventive prescription medications for migraine J Manag Care Spec Pharm 26 1334-1343
[3]
Alahdab F(2016)Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO Study Mayo Clin Proc 26 1344-1352
[4]
Amit AML(2020)Effect of headache-free days on disability, productivity, quality of life, and costs among individuals with migraine J Manag Care Spec Pharm 78 1337-1345
[5]
Barnighausen TW(2012)Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American academy of neurology and the American headache society Neurology 37 470-485
[6]
Beghi E(2017)Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis Cephalalgia 20 22-33
[7]
Buse DC(2014)Systematic review of migraine prophylaxis adherence and persistence J Manag Care Pharm 53 644-655
[8]
Yugrakh MS(2013)Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the Second International Burden of Migraine Study (IBMS-II) Headache 319 1999-2008
[9]
Lee LK(2018)Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial JAMA 394 1030-1040
[10]
Bell J(2019)Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial Lancet 377 2113-2122